GlobeNewswire: Goodwin Biotechnology Incorporated Contains the last 10 of 7 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:19:08ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2009/09/14/404442/173069/en/Goodwin-Biotechnology-Inc-Completes-cGMP-Manufacturing-of-AREVA-Med-s-Conjugate.html?f=22&fvtc=4&fvtv=8194Goodwin Biotechnology Inc. Completes cGMP Manufacturing of AREVA Med's Conjugate2009-09-14T12:00:00Z<![CDATA[PLANTATION, Fla., Sept. 14, 2009 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) announced today the completion of the cGMP manufacturing and vialing of AREVA Med's monoclonal antibody-chelator conjugate. As part of AREVA Med's Lead-212 (212Pb) initiative, the conjugate will be used in Phase I clinical trials to treat several types of deadly forms of cancers. AREVA Med will benefit from the vast expertise in the nuclear industry from AREVA, its parent company, that allowed for the production of this radioisotope previously considered a scarce resource.
]]>https://www.globenewswire.com/news-release/2008/12/12/389595/156113/en/Goodwin-Biotechnology-Inc-Completes-Development-of-AREVA-s-New-Cancer-Treatment.html?f=22&fvtc=4&fvtv=8194Goodwin Biotechnology Inc. Completes Development of AREVA's New Cancer Treatment2008-12-12T12:00:00Z<![CDATA[PLANTATION, Fla., Dec. 12, 2008 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) announced today the successful completion of the development work for the new AREVA drug that will be radio-labeled by the NCI with lead-212 and used to fight cancer. The completion of this step allows for the cGMP manufacturing of the conjugated drug that is expected to enter a Phase I clinical trial in 2009.
]]>https://www.globenewswire.com/news-release/2008/12/12/24334/0/en/Goodwin-Biotechnology-Inc-Completes-Development-of-AREVA-s-New-Cancer-Treatment.html?f=22&fvtc=4&fvtv=8194Goodwin Biotechnology Inc. Completes Development of AREVA's New Cancer Treatment2008-12-12T12:00:00Z<![CDATA[PLANTATION, Fla., Dec. 12, 2008 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc.
(GBI) announced today the successful completion of the development work for the
new AREVA drug that will be radio-labeled by the NCI with lead-212 and used to
fight cancer. The completion of this step allows for the cGMP manufacturing of
the conjugated drug that is expected to enter a Phase I clinical trial in 2009.
Stephanie Finnegan, CEO of GBI said "We are proud that AREVA chose us to play a
key role in...]]>https://www.globenewswire.com/news-release/2008/12/12/23963/0/de/Goodwin-Biotechnology-Inc-beendet-Entwicklung-von-AREVAs-neuer-Krebsbehandlung.html?f=22&fvtc=4&fvtv=8194Goodwin Biotechnology Inc. beendet Entwicklung von AREVAs neuer Krebsbehandlung2008-12-12T12:00:00Z<![CDATA[PLANTATION, Fla., 12. Dez. 2008 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc.
(GBI) hat heute die erfolgreiche Beendigung der Entwicklungsarbeit für das neue
AREVA Medikament bekannt gegeben, das durch das NCI mit Lead-212 radioaktiv
markiert und im Kampf gegen Krebs eingesetzt werden wird. Die Realisierung
dieses Schrittes kalkuliert die cGMP Herstellung des damit verbundenen
Medikaments mit ein, das voraussichtlich 2009 eine Phase I klinische Studie
beginnen wird..
Stephanie...]]>https://www.globenewswire.com/news-release/2008/12/12/23964/0/fr/Goodwin-Biotechnology-Inc-ach%C3%A8ve-le-d%C3%A9veloppement-du-nouveau-traitement-contre-le-cancer-d-AREVA.html?f=22&fvtc=4&fvtv=8194Goodwin Biotechnology Inc. achève le développement du nouveau traitement contre le cancer d'AREVA2008-12-12T12:00:00Z<![CDATA[Goodwin Biotechnology Inc. achève le développement du nouveau traitement contre
le cancer d'AREVA
PLANTATION, Floride, le 12 décembre 2008 (GLOBE NEWSWIRE) -- Goodwin
Biotechnology Inc. (GBI) annonce aujourd'hui la réussite de son travail de mise
au point du nouveau médicament AREVA qui sera radiomarqué au plomb-212 par le
NCI et utilisé pour combattre le cancer. L'achèvement de cette étape permet la
manufacture conforme aux BPF du médicament conjugué qui devrait entrer en...]]>https://www.globenewswire.com/news-release/2008/07/21/381549/146639/en/Goodwin-Biotechnology-s-Manufactured-Melanin-Binding-Antibody-Used-in-Successful-Melanoma-Trial.html?f=22&fvtc=4&fvtv=8194Goodwin Biotechnology's Manufactured Melanin-Binding Antibody Used in Successful Melanoma Trial2008-07-21T11:00:00Z<![CDATA[PLANTATION, Fla., July 21, 2008 (PRIME NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) today announced that the melanin-binding IgM antibody manufactured by the company was used in a successful Phase I clinical trial for the treatment of melanoma. The encouraging results, conducted by Pain Therapeutics, Inc. and its collaborators, were announced earlier this month. GBI was selected to develop the process and produce the preclinical and clinical material for this and future trials.
]]>https://www.globenewswire.com/news-release/2008/06/30/380553/145443/en/AREVA-Selects-Goodwin-Biotechnology-Inc-As-a-Partner-for-Its-New-Cancer-Treatment.html?f=22&fvtc=4&fvtv=8194AREVA Selects Goodwin Biotechnology Inc. As a Partner for Its New Cancer Treatment2008-06-30T11:00:00Z<![CDATA[PLANTATION, Fla., June 30, 2008 (PRIME NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) disclosed today that it has begun process development toward AREVA's lead-212 initiative to treat cancer. As part of this agreement, GBI will manufacture a new conjugated drug that will be radiolabeled by the NCI with lead-212. AREVA's long-term expertise in the nuclear industry allowed for the production of this radioisotope previously considered a scarce resource.
]]>